TMS Nearby

Spravato (Esketamine) in Santa Maria, California

Compare 2 Spravato (Esketamine) clinics in Santa Maria, California that offer care for treatment-resistant depression and major depressive disorder. Review services, ratings, and contact details to find the right provider near you.
Mental health clinic illustration

Clinics

2 clinics shown

  • Santa Barbara County Mental Health Services - Santa Maria Facility

    Santa Barbara County Mental Health Services operates a public mental health facility on West Foster Road in Santa Maria, providing outpatient psychiatric care and case management for county residents. The clinic serves adults and children with serious mental illness, offering medication management, therapy, and crisis intervention through county-funded programs. Eligibility and services are determined by county mental health criteria; specific treatment modalities such as TMS or esketamine are not listed in available facility information. Patients should contact the clinic directly to confirm available services and insurance acceptance.

    No reviews yet
    View Details

  • Transitions-Mental Health Association

    Mental health services for adults are provided at Transitions-Mental Health Association on Inger Drive in Santa Maria. The organization operates as a community-based mental health service, though specific treatment modalities such as TMS, esketamine, or ketamine therapy are not detailed in available information. Patients seeking procedural interventions for treatment-resistant depression should contact the practice directly to confirm which services are currently offered beyond standard outpatient psychiatric care.

    No reviews yet
    View Details

About Spravato (Esketamine)

Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.

Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.

Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.

The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.

Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.